The majority of GLP-1 medications are only approved for adults 18 years and older
Article PubMed Google Scholar Prado, C
The valuation was north of $500,000,000, indicating investor interest
The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital
In vitro studies have shown that addition of DPP-4 is associated with impaired insulin signaling in primary human adipocytes, skeletal muscle, and smooth muscle cells (79), while conversely, silencing Dpp4 (using short interfering RNA) resulted in improved adipocyte insulin responsiveness (89)
10.1016/j.molmet.2017.05.002 107 ShinN.-R.LeeJ.-C.LeeH.-Y.KimM.-S.WhonT